Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.960
-0.050 (-2.49%)
At close: Mar 28, 2025, 4:00 PM
1.930
-0.030 (-1.53%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Humacyte Employees
As of December 31, 2023, Humacyte had 185 total employees, including 183 full-time and 2 part-time employees. The number of employees increased by 21 or 12.80% compared to the previous year.
Employees
185
Change (1Y)
21
Growth (1Y)
12.80%
Revenue / Employee
n/a
Profits / Employee
-$803,789
Market Cap
252.19M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 185 | 21 | 12.80% |
Dec 31, 2022 | 164 | 18 | 12.33% |
Dec 31, 2021 | 146 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
HUMA News
- 2 days ago - Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 2 days ago - Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 days ago - Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 - GlobeNewsWire
- 5 days ago - Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 5 days ago - Humacyte, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 20 days ago - Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics - GlobeNewsWire
- 24 days ago - Trestle Bio Announces Research Collaboration with Humacyte - Business Wire
- 27 days ago - Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 - GlobeNewsWire